All stock lists
Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
8.10-0.10 (-1.28%)
Insider Score
––Not scored
RNA Insider Score
Insiders here have filed 8 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
RNA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 3.00 M | 19.64 M | 859.00 K | 12.34 M | 3.85 M | — |
| Revenue Growth (YoY) | -21.91 % | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| SG&A Expense | 10.28 M | 20.26 M | 30.40 M | 5.77 M | 3.42 M | — |
| R&D Expense | 15.34 M | 16.66 M | 18.50 M | 15.03 M | 13.29 M | — |
| Operating Expenses | 25.62 M | 36.91 M | 48.89 M | 20.80 M | 16.71 M | — |
| Operating Income | -22.62 M | -17.28 M | -48.03 M | -8.46 M | -12.86 M | — |
| Pretax Income | -20.19 M | -16.63 M | -48.03 M | -8.46 M | -12.88 M | — |
| Tax Provision | — | — | 34.00 K | — | — | — |
| Net Income | -20.19 M | -16.63 M | -48.07 M | -8.29 M | -12.88 M | — |
| EPS (Basic) | -1.18 | -0.97 | — | — | -0.75 | -0.44 |
| EPS (Diluted) | -1.18 | -0.97 | — | — | -0.75 | -0.44 |
| Shares Outstanding | 17.11 M | 17.11 M | — | — | 17.11 M | 17.08 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.